Disclosures for "A Real-world Study of the Effectiveness and Safety of Ravulizumab in AQP4-Ab+ NMOSD Patients with Suboptimal Response to Satralizumab in Japan - Interim Analysis"
-
Wakiro Sato has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Biogen. Wakiro Sato has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis Pharma. Wakiro Sato has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Mitsubishi Tanabe Pharma.
-
Dr. Amano has nothing to disclose.
-
Tomoko Okamoto has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis. The institution of Tomoko Okamoto has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Alexion Pharma G.K.. Tomoko Okamoto has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biogen. Tomoko Okamoto has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Chugai Pharmaceutical Co., Ltd.. Tomoko Okamoto has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Teijin Pharma Limited.. The institution of Tomoko Okamoto has received research support from Alexion Pharma G.K.. The institution of Tomoko Okamoto has received research support from Sanofi. The institution of Tomoko Okamoto has received research support from Novartis. The institution of Tomoko Okamoto has received research support from UCB Japan Co., Ltd. The institution of Tomoko Okamoto has received research support from Biogen Japan Ltd.. The institution of Tomoko Okamoto has received research support from Chugai Pharmaceutical Co., Ltd.. The institution of Tomoko Okamoto has received research support from Mitsubishi Tanabe Pharma Corporation. Tomoko Okamoto has received intellectual property interests from a discovery or technology relating to health care.
-
Author has nothing to disclose
-
Dr. Katsumoto has nothing to disclose.
-
Reiko Saika has nothing to disclose.
-
The institution of Dr. Takahashi has received research support from Nihon Medi-Physics Co. Limit.. The institution of Dr. Takahashi has received research support from Takeda Pharmaceutical Company Limited.
-
Author has nothing to disclose
-
Prof. Inoue has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion Pharmaceuticals. Prof. Inoue has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Swedish Orphan Biovitrum Japan. Prof. Inoue has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi. Prof. Inoue has received personal compensation in the range of $500-$4,999 for serving as a Consultant for CSL Behring. Prof. Inoue has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Alexion Pharmaceuticals. Prof. Inoue has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for UCBJapan. Prof. Inoue has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Chugai Pharmaceutical. Prof. Inoue has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis Japan. Prof. Inoue has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sanwa Kagaku Kenkyusyo . Prof. Inoue has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Swedish Orphan Biovitrum Japan. Prof. Inoue has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Kissei Pharmaceutical. Prof. Inoue has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Asahi Kasei Pharma. The institution of Prof. Inoue has received research support from Japan Agency for Medical Research and Development. The institution of Prof. Inoue has received research support from Ministry of Health, Labour and Welfare. The institution of Prof. Inoue has received research support from National Center of Neurology and Psychiatry.
-
Sami Fam has received personal compensation for serving as an employee of Alexion Pharmaceuticals. Sami Fam has or had stock in Astra Zeneca.
-
Dr. Yamamura has nothing to disclose.